$SRXH News

SRX Global Provides Shareholder Update on Portfolio Company, ARMR Sciences, a Clinical-Stage Biodefense Company

SRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers

SRX Global Inc (SRXH) (Q3 2026) Earnings Call Highlights: Strategic EMJX Acquisition and Record ...

SRX HealthSolutions Q3 2026 Earnings Call: Complete Transcript

SRX HealthSolutions Q3 EPS $(0.36) Up From $(44.51) YoY, Sales $3.392M Up From $2.673M YoY

SRX Global to Host Fiscal Third Quarter 2026 Conference Call on August 13 at 4:30 p.m. ET

SRX Global (SRXH) Acquires Stake in Vistagen Therapeutics

SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN)

SRX Global Portfolio Company Smartkem, Inc. (NASDAQ: SMTK) Announces Merger

SRX Global Regains Full Compliance with NYSE American Listing Standards

SRX Global Reports 26% Returns From Paper-Traded EMJX From Feb. 11 To July 10

SRXH Stock Falls Premarket Ahead Of Eric Jackson's Fireside Chat — Traders Brace For Buyback Clues And CEO Spotlight

SRX Global Management Team to Host Virtual Fireside Chat on July 14, 2026, and Issues Letter to Shareholders

SRX Global Board of Directors Authorizes Stock Repurchase Plan of Up to 10 Million Shares or Up to 50% of its Shares Outstanding

SRX Global Authorizes $20M Share Buyback Program For Up To 10M Shares, Or 50% Of Outstanding Stock

SRX Global Reports Preliminary Net Asset Value of Approximately $3.07 Per Share and Over $55 Million in Cash and Short-Term Investments(1)

SRX Global Estimates Net Asset Value Of $60M, Or $3.07 Per Share; Reports No Debt Outstanding, As Of June 30, 2026

SRX Global Declares One-Time Cash Dividend

Why SRX Global Shares Are Trading Lower On Wednesday

SRX Global Announces Share Consolidation